You are here

Dr. Christopher Mason

Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant (P01) from the National Cancer Institute (NCI) to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time.

On a Tuesday in early June, just days before summer break, dozens of third-year medical students gathered in the Belfer Research Building to present findings from independent research projects they’d been working on since February.

Errors in the regulation of gene expression may contribute to the development of a common form of blood cancer and point to potential treatment strategies, according to a new study by scientists from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center.